Deferring Whole-Brain Radiotherapy with Stereotactic Radiosurgery for Brain Metastases: A Prospective Cohort Study

Abstract Background Whole-brain radiotherapy (WBRT) provides intracranial disease control but is associated with neurocognitive toxicity. Following stereotactic radiosurgery (SRS), selected intracranial recurrences may be managed with further focal treatment rather than immediate WBRT. We evaluated recurrence patterns, salvage treatment, and subsequent WBRT use in a prospective SRS/stereotactic radiotherapy (SRT) cohort. Methods Adults with brain metastases treated under a prospective institutional SRS/SRT protocol were included. Of 298 patients, 269 had received neither prior WBRT nor WBRT as part of index treatment and formed the primary cohort. Intracranial recurrence, salvage-treatment sequence, and radiation necrosis (RN) were recorded. Cumulative incidence of salvage WBRT and overall RN was estimated with death as a competing event; WBRT-free survival, defined as time to salvage WBRT or death, was estimated using Kaplan–Meier analysis. Results Median follow-up was 12.8 months. Intracranial recurrence occurred in 110 of 269 patients (40.9%). Repeat SRS/SRT was first salvage in 47 patients, of whom six subsequently received WBRT. Overall, 34 patients (12.6%) received salvage WBRT. WBRT was selected as first salvage in 30.8%, 10.4%, and 38.8% of patients with isolated in-field, isolated out-of-field, and combined recurrence, respectively (p = 0.005). With death as a competing event, cumulative incidence of salvage WBRT was 3.1%, 8.3%, and 13.2% at 6, 12, and 24 months. Subsequent WBRT incidence after repeat SRS/SRT was 9.5% at 6 months and 12.1% at 12 months. Median WBRT-free survival was 14.6 months (95% CI, 11.7–17.4). Symptomatic RN occurred in 21 patients (7.8%); the 24-month cumulative incidence of overall RN was 10.2%. Conclusions Following initial SRS/SRT, intracranial tumour control was observed in 59.1% of patients, and 87.4% remained free from WBRT at their last recorded follow-up. Among selected patients receiving repeat SRS/SRT as first salvage, 87.2% (41/47) had no subsequent WBRT during available follow-up. These findings support continued focal intracranial management in selected patients, with potential neurocognitive benefits from limiting WBRT-associated toxicity.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-16
DOI
https://doi.org/10.21203/rs.3.rs-11215140/v1
Primary Topic
Brain Metastases and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Deferring Whole-Brain Radiotherapy with Stereotactic Radiosurgery for Brain Metastases: A Prospective Cohort Study

Ajay Sasidharan, Debnarayan Dutta, Rajesh Kannan, Pranav Nair et al.
Research Square
Brain Metastases and Treatment
preprint

Deferring Whole-Brain Radiotherapy with Stereotactic Radiosurgery for Brain Metastases: A Prospective Cohort Study

Ajay Sasidharan, Debnarayan Dutta, Rajesh Kannan, Pranav Nair, Haridas Mohanachandran Nair, Veena Krishna, Haripriya Surendran, Kalavagunta Sruthi, Annex EH, Aaditya Madan, Anoop R, Pushpaja KU
preprint en

Abstract

Abstract Background Whole-brain radiotherapy (WBRT) provides intracranial disease control but is associated with neurocognitive toxicity. Following stereotactic radiosurgery (SRS), selected intracranial recurrences may be managed with further focal treatment rather than immediate WBRT. We evaluated recurrence patterns, salvage treatment, and subsequent WBRT use in a prospective SRS/stereotactic radiotherapy (SRT) cohort. Methods Adults with brain metastases treated under a prospective institutional SRS/SRT protocol were included. Of 298 patients, 269 had received neither prior WBRT nor WBRT as part of index treatment and formed the primary cohort. Intracranial recurrence, salvage-treatment sequence, and radiation necrosis (RN) were recorded. Cumulative incidence of salvage WBRT and overall RN was estimated with death as a competing event; WBRT-free survival, defined as time to salvage WBRT or death, was estimated using Kaplan–Meier analysis. Results Median follow-up was 12.8 months. Intracranial recurrence occurred in 110 of 269 patients (40.9%). Repeat SRS/SRT was first salvage in 47 patients, of whom six subsequently received WBRT. Overall, 34 patients (12.6%) received salvage WBRT. WBRT was selected as first salvage in 30.8%, 10.4%, and 38.8% of patients with isolated in-field, isolated out-of-field, and combined recurrence, respectively (p = 0.005). With death as a competing event, cumulative incidence of salvage WBRT was 3.1%, 8.3%, and 13.2% at 6, 12, and 24 months. Subsequent WBRT incidence after repeat SRS/SRT was 9.5% at 6 months and 12.1% at 12 months. Median WBRT-free survival was 14.6 months (95% CI, 11.7–17.4). Symptomatic RN occurred in 21 patients (7.8%); the 24-month cumulative incidence of overall RN was 10.2%. Conclusions Following initial SRS/SRT, intracranial tumour control was observed in 59.1% of patients, and 87.4% remained free from WBRT at their last recorded follow-up. Among selected patients receiving repeat SRS/SRT as first salvage, 87.2% (41/47) had no subsequent WBRT during available follow-up. These findings support continued focal intracranial management in selected patients, with potential neurocognitive benefits from limiting WBRT-associated toxicity.

Research Square
Amrita Vishwa Vidyapeetham (IN)
Good health and well-being
Brain Metastases and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon